ALLMedicine™ Hypomagnesemia Center
Research & Reviews 619 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9368240
International Journal of Environmental Research and Publi... Choi YJ, Choi CY et. al.
Aug 13th, 2022 - Despite substantially elevated risk of serious adverse events (SAEs) from targeted therapy in combination with chemotherapy, comprehensive pharmacovigilance research is limited. This study aims to systematically assess SAE risks of commonly prescr...
https://doi.org/10.1080/08923973.2022.2112222
Immunopharmacology and Immunotoxicology; Liu T, Jiang S et. al.
Aug 12th, 2022 - Cetuximab and panitumumab are common antibodies against epidermal growth factor receptor (EGFR) that can be used in combination with chemotherapy for the treatment of metastatic colorectal cancer (mCRC). Although these two drugs are considered to ...
https://doi.org/10.1097/MNH.0000000000000819
Current Opinion in Nephrology and Hypertension; Turcotte A, Achi S et. al.
Jul 28th, 2022 - Hypernatremia, hyperphosphatemia, hypocalcaemia, hyperkalaemia and hypermagnesemia are electrolytes disturbances that can arise in cancer patients in relation to unique causes that are related to the cancer itself or its treatment and can lead to ...
https://doi.org/10.1097/MNH.0000000000000818
Current Opinion in Nephrology and Hypertension; Schlingmann KP, de Baaij JHF
Jul 28th, 2022 - Gitelman syndrome is a recessive salt-wasting disorder characterized by hypomagnesemia, hypokalemia, metabolic alkalosis and hypocalciuria. The majority of patients are explained by mutations and deletions in the SLC12A3 gene, encoding the Na+-Cl-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9327143
BMC Nephrology; Guo X, Yu S et. al.
Jul 27th, 2022 - Gitelman syndrome (GS) is a rare autosomal recessive inherited salt-losing tubulopathy (SLT). Here, we report, for the first time, a case of GS overlapping nephrotic syndrome (NS) related to PLA2R-associated membranous nephropathy (MN). We describ...
Drugs 115 results see all →
Clinicaltrials.gov 47 results
https://clinicaltrials.gov/ct2/show/NCT05474157
Jul 26th, 2022 - Patients with acute respiratory distress syndrome (ARDS) could develop muscle weakness associated with impairment of physical function defined as intensive care unit acquired weakness. Significant muscle loss occurs in the first week of the Intens...
https://clinicaltrials.gov/ct2/show/NCT04310826
Jun 24th, 2022 - PRIMARY OBJECTIVE: I. Evaluate intervention feasibility. SECONDARY OBJECTIVE: I. Evaluate occurrence of hypomagnesemia and the need for a pharmacy regimen including oral and intravenous magnesium dosage. EXPLORATORY OBJECTIVE: I. Explore changes i...
https://clinicaltrials.gov/ct2/show/NCT03812380
Jun 1st, 2022 - In a single-dose bioavailability study, the investigators showed previously that provision of calcium and magnesium in a soluble form as EffCaMgCit improved intestinal absorption of calcium and magnesium and suppressed parathyroid function during ...
https://clinicaltrials.gov/ct2/show/NCT04166877
May 18th, 2022 - This is a single center, double blind, randomized controlled study to demonstrate the effectiveness of continuous, intravenous administration of magnesium sulfate as compared to placebo in decreasing pain in critically injured patients. Study Hypo...
https://clinicaltrials.gov/ct2/show/NCT05352880
Apr 29th, 2022 - Magnesium (Mg) is the fourth cation in the body and the second most prevalent intracellular cation. Intracellular magnesium concentrations range from 5 to 20 mmol/L; 1-5% of it is ionized, the remainder is bound to proteins. Extracellular Mg repre...
News 76 results
https://www.onclive.com/view/sl-172154-shows-favorable-tolerability-in-platinum-resistant-ovarian-cancer
Nov 17th, 2021 - The investigative agent SL-172154 (SIRPα-Fc-CD40L) was found to be well tolerated, with no dose-limiting toxicities (DLTs) observed, in patients with platinum-resistant ovarian cancer, according to findings from a phase 1 dose-escalation trial pre...
https://www.mdedge.com/fedprac/avaho/article/246950/oncology/novel-and-alternative-strategies-management-panitumumab
Katie Rogers, PharmD candidate (rogers.a.katie@utexas.edu), Sierra Vig, PharmD, BCOP, BCPS et. al.
Oct 1st, 2021 - Background Panitumumab is an epidermal growth factor receptor (EGFR) inhibiting monoclonal antibody approved for the treatment of RAS wild-type metastatic colorectal cancer (mCRC), which has an incidence of hypomagnesemia of approximately 35%. Gra.
https://www.onclive.com/view/thoracic-leaders-examine-novel-treatment-options-in-mesothelioma
Jun 23rd, 2021 - In a special OncLive video program, The Board, Joshua M. Bauml, MD, assistant professor of medicine, Perelman School of Medicine, University of Pennsylvania, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual...
https://www.onclive.com/view/cetuximab-safety-profile-in-head-and-neck-cancer
Apr 2nd, 2021 - For High-Definition, Click Toxicities associated with cetuximab tend to be more tolerable than those observed with cytotoxic chemotherapy. The most concerning side effect, notes Robert Ferris, MD, is an anaphylactic infusion reaction, attributed...
https://www.onclive.com/view/bcl-2-inhibitor-venetoclax-demonstrates-activity-in-pretreated-aml
Dec 20th, 2020 - Marina Konopleva, MD, PhD Some patients with heavily treated acute myelogenous leukemia (AML) benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199), according to a phase II clinical study presented at the 2014 ASH Annual Meeting....